Abstract Background: Transarterial Chemoembolization (TACE) is recommended as a treatment for unresectable Hepatocellular Carcinoma (HCC) in patients with normal compensated liver. The efficacy of TACE in cirrhotic patients with compromised liver function is unknown. Aim of Study: To evaluate the outcome following Tran-sarterial Chemoembolization (TACE) in patients with unap-plicable locoregional therapy in Hepatocellular Carcinoma (HCC). Patients and Methods: This Prospective Cohort study conducted on 50 patients with HCC at Tropical Medicine and Gastroenterology Department Qena University Hospital. Results: 56% of patients reached complete response within one month of treatment in mean duration of follow-up of 58.28 months, 66% of patients had recurrence 40% in <1 year and 26% 1-2 years, 34% of recurrence were target tumor progression, 20% intrahepatic new lesion and 12% both, total deaths were 46% of patients. Conclusions: TACE offers a reasonable palliative therapy for HCC.